Noppadol Siritanaratkul

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Tadeusz Robak, Huiqiang Huang, Jie Jin et al. · New England Journal of Medicine · 2015 · 375 citations · Full text

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Haematology · 2016 · 143 citations

Hematological Malignancy, Oncology, Overall Survival +7

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Alì Taher, John B. Porter, Vip Viprakasit et al. · Blood · 2012 · 141 citations · Full text

Improvement in oxidative stress and antioxidant parameters in β-thalassemia/Hb E patients treated with curcuminoids

Ruchaneekorn W. Kalpravidh, Noppadol Siritanaratkul, Praphaipit Insain et al. · Clinical Biochemistry · 2009 · 133 citations

Lipid Peroxidation, Pharmacology, β-Thalassemia/hb E Patients +5